INTRAVACC BV

Their core work

Intravacc is a Dutch contract development and manufacturing organization (CDMO) specialized in vaccines. They provide end-to-end vaccine development services including process development, manufacturing, analytical testing, and quality control for both human and veterinary vaccines. Within H2020, they contributed manufacturing and testing expertise to pan-European vaccine infrastructure initiatives, supporting consistency testing methods and helping design continent-wide R&D platforms for prophylactic and therapeutic vaccines.

What they specialise in

How they've shifted over time

Intravacc's early H2020 involvement (2016) centered on applied vaccine manufacturing — specifically lot-to-lot consistency testing and quality control (VAC2VAC). From 2017 onward, their focus broadened to European-scale vaccine R&D infrastructure, participating in both the operational phase (TRANSVAC2) and the design study (TRANSVAC-DS) for a permanent European vaccine platform. This shift suggests a move from narrow technical services toward a strategic role in shaping Europe's vaccine development ecosystem.

Intravacc is positioning itself as a key infrastructure partner for pan-European vaccine development platforms, moving beyond project-level testing services toward systemic infrastructure roles.

How they like to work

Intravacc participates exclusively as a partner, never as coordinator, contributing specialized manufacturing and testing expertise to large consortia. With 54 unique partners across 12 countries from just 3 projects, they operate within very large, multi-national networks — typical of infrastructure-type projects. This suggests they are a trusted technical contributor that large consortia seek out for their specific vaccine development capabilities.

Despite only three projects, Intravacc has built a broad network of 54 partners across 12 countries, reflecting the large-scale nature of the vaccine infrastructure consortia they join. Their network spans much of Europe, consistent with their involvement in continent-wide research infrastructure initiatives.

What sets them apart

Intravacc occupies a rare niche as a dedicated vaccine CDMO with deep expertise in both development and manufacturing — a capability few European organizations offer independently. Their involvement in both the operational TRANSVAC2 infrastructure and its design study successor signals that they are considered essential to Europe's vaccine preparedness architecture. For consortium builders, they bring hands-on manufacturing and QC capability that bridges the gap between academic vaccine research and industrial-scale production.

Highlights from their portfolio

• TRANSVAC2
  Largest project by funding (EUR 138,599 to Intravacc), building the core European Vaccine Research and Development Infrastructure spanning human and veterinary applications.
• VAC2VAC
  Addressed a critical regulatory challenge — proving vaccine lot consistency through analytical testing rather than costly animal studies, with direct impact on manufacturing efficiency.